1. Home
  2. OGI vs CBIO Comparison

OGI vs CBIO Comparison

Compare OGI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Organigram Holdings Inc.

OGI

Organigram Holdings Inc.

HOLD

Current Price

$1.65

Market Cap

215.8M

Sector

Health Care

ML Signal

HOLD

CBIO

Crescent Biopharma Inc. Common Stock

HOLD

Current Price

$13.07

Market Cap

252.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OGI
CBIO
Founded
2013
2003
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
215.8M
252.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OGI
CBIO
Price
$1.65
$13.07
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$25.60
AVG Volume (30 Days)
525.2K
182.3K
Earning Date
12-16-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$164,107,753.00
N/A
Revenue This Year
$59.31
N/A
Revenue Next Year
$15.12
N/A
P/E Ratio
$38.60
N/A
Revenue Growth
50.01
N/A
52 Week Low
$0.85
$9.81
52 Week High
$2.08
$21.40

Technical Indicators

Market Signals
Indicator
OGI
CBIO
Relative Strength Index (RSI) 52.83 47.55
Support Level $1.45 $12.59
Resistance Level $1.72 $16.35
Average True Range (ATR) 0.08 1.08
MACD 0.02 -0.10
Stochastic Oscillator 70.37 18.99

Price Performance

Historical Comparison
OGI
CBIO

About OGI Organigram Holdings Inc.

Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: